Table 2: Basal characteristics of the study population.

CharacteristicsNo-SMS* group ()SMS group ()Total () value

Age, y (range)55.8 ± 12.3 (20–80)53.7 ± 10.4 (26–77)54.7 ± 11.4 (20–80) 0.143
Gender (male : female)63 (46.7) : 72 (53.3) 63 (46.3) : 73 (53.7) 126 (46.5) : 145 (53.5)0.955
Body mass index, kg/m2 (range)23.2 ± 2.8 (16–32)23.6 ± 2.6 (16.7–32.9) 23.4 ± 2.7 (16.0–32.9)0.210
History of colonoscopy 75 (55.6)61 (44.9)136 (50.2)0.078
Abdominal or pelvic surgery 36 (26.7)80 (58.8) 116 (42.8)<0.001
Familial history of colorectal cancer 8 (5.9)9 (6.6)17 (6.3)0.814
Chronic comorbid disease
 Diabetes 9 (6.7)6 (4.4)15 (5.5)0.417
 Thyroid disease 3 (2.2)6 (4.4)9 (3.3)0.315
Indication of colonoscopy<0.001
 Screening 53 (39.3)90 (66.2)143 (52.8)
 Surveillance 25 (18.5)15 (11.0) 40 (14.8)
 Symptoms57 (42.2)31 (22.8)88 (32.5)
Symptoms
 Rectal bleeding 11 (8.1)1 (0.7)12 (4.4)0.003
 Anemia 1 (0.7)8 (5.9)9 (3.3)0.018
 Positive stool occult
  blood
1 (0.7)01 (0.4)0.315
 Significant weight loss 2 (1.5)02 (0.7)0.154
 Abdominal pain/discomfort/bloating 34 (25.2)14 (10.3)48 (17.7)0.005
 Change in bowel habits 7 (5.2)07 (2.6)0.007
 Constipation 2 (1.5)3 (2.2)5 (1.8)0.658
 Diarrhea 5 (3.7)5 (3.7)10 (3.7)0.991
Mean PC interval, hour (range)7:03 ± 1:38 (2:30–13:00)5:02 ± 2:02 (1:00–9:00)6:02 ± 2:06 (1:00–13:00)<0.001
Compliance with diet instructions108 (80)120 (88.2)228 (84.1)0.064
≥75% of PEG ingested130 (96.3)136 (100)266 (98.2)0.023
Intubation to cecum135 (100)135 (99.3)270 (99.6)0.318
Polyp detection rate (%)37.8 41.239.50.567
Adenoma detection rate (%)31.130.930.10.968
Colonoscopy withdrawal time, second (range)371.3 ± 39.5 (258–491)379.6 ± 47.7 (258–755)375.4 ± 44.0 (258–755)0.119

Values are mean ± standard deviation or number (%).
SMS*, short message service of cellular phone; PC interval, preparation-to-colonoscopy interval; PEG, polyethylene glycol.